Drugs / Navepegritide
Navepegritide
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | YUVIWEL | — | 2026-02-27 | fda.gov ↗ |
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 25 trials | ||||||
| Phase 2 | NCT06732895 | Dec 2024 → Aug 2027 expected | achondroplasia | Ascendis Pharma A/S | Recruiting | No outcome recorded |
| Phase 2 | NCT06433557 | Jul 2024 → Nov 2025 overdue | achondroplasia | Ascendis Pharma Growth Disorders A/S | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06079398 | Jan 2024 → Dec 2027 expected | achondroplasia | Ascendis Pharma A/S | Recruiting | No outcome recorded |
| Phase 2 | NCT05246033 | Jan 2022 → Mar 2023 | achondroplasia | Ascendis Pharma A/S | Unknown | No outcome recorded |
| Phase 2 | NCT04085523 | Jun 2020 → Sep 2022 | achondroplasia | Ascendis Pharma A/S | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05929807 | Jun 2023 → Jan 2039 expected | achondroplasia | Ascendis Pharma Growth Disorders A/S | Enrolling by invitation | No outcome recorded |
| Phase 2/3 | NCT05598320 | Mar 2023 → Aug 2024 | achondroplasia | Ascendis Pharma Growth Disorders A/S | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | navepegritide | “Once-weekly TransCon CNP (navepegritide) in children with achondroplasia” PMID 37823031 ↗ Oct 2023 |
| Known as | Navepegritida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594507 ↗ |
| Known as | TransCon CNP | “Navepegritide (TransCon CNP) 100 micrograms per kilogram (µg/kg) delivered once weekly by subcutaneous injection” NCT05598320 ↗4“100 μg CNP/kg of Navepegritide (TransCon CNP) administered SC once-weekly” NCT06079398 ↗ |
| Known as | Transcon cnp-38 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594507 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4594507 ↗ |
| Route | Subcutaneous | “administered by subcutaneous injection via syringe and needle.” NCT04085523 ↗ |